Docket No.: 22116-00011-US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mark R. Burns

Application No.: 10/805,222 | Confirmation No.: 9133

Filed: March 22, 2004 | Art Unit: 1625

For: TETRAHYDRO-β-CARBOLINE COMPOUNDS AND USE THEREOF | Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent,

publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 22116-00011-US.

Dated: 12-9-04

Respectfully submitted,

By

Burton A. Amernick
Registration No.: 24,852
CONNOLLY BOVE LODGE & HUTZ LLP
1990 M Street, N.W., Suite 800
Washington, DC 20036-3425
(202) 331-7111
(202) 293-6229 (Fax)
Attorney for Applicant

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/805,222-Conf. #9133
Filing Date	March 22, 2004
First Named Inventor	Mark R. Burns
Art Unit	1625
Examiner Name	Not Yet Assigned
Attorney Docket Number	22116-00011-US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	Tetrahydro-β-carbolines, Potential Neuroactive Alkaloids, in Chocolate and Cocoa by Tomas Herraiz, J. Agric. Food Chem. 2000, 48, pages 4900-4904	
	CB	Glutamate Receptors in the Mammalian Central Nervous System, by Seiji Ozawa et al., Progress in Neurobiology vol. 54, pages. 581-618, 1998	
	CC	Glutamate Neurotoxicity and Diseases of the Nervous System, by Dennis Choi, Neuron, vol. 1, pages 623-634, October 1988	
	CD	NMDA receptors as targets for drug action in neuropathic pain, by Chris Parsons, European Journal of Pharmacology 429, 2001, pages 71-78	
	CE	Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats, by Zofia Rogoz et al., Neuropharmacology 42, 2002, pages 1024-1030	
	CF	Modulation of the NMDA Receptor by Polyamines, by Keith Williams, et al., Life Sciences, vol. 48, pages 469-498, 1991	
	CG	Characterization of the Effects of Polyamines on [^{125}] MK-801 Binding to Recombinant *N*-Methyl-D-Aspartate Receptors, by Terre Sharma et al., The Journal of Pharmacology and Experimental Therapeutics, 1999, pages 1041-1047	
	CH	Endogenous indoles as novel polyamine site ligands as the *N*-methyl-D-aspartate receptor complex, by David Worthen et al., Brain Research 890 2001, pages 343-346	
	CI	N^1-Dansyl-Spermine and N^1-(n-Octanesulfonyl)-Spermine, Novel Glutamate Receptor Antagonists: Block and Permeation of N-Methyl-D-Aspartate Receptors, by James Chao et al., Molecular Pharmacology, pages 861-871 1997	
	CJ	Functional antagonists at the NMDA receptor complex exhibit antidepressant actions, by Ramon Trullas et al., European Journal of Pharmacology 185 1990, pages 1-10	
	CK	Potential Antidepressive Properties of Amantadine, Memantine and Bifemelane, Elzbieta Moryl et al., Pharmacology & Toxicology 1993, 72, pages 394-397	
	CL	The *N*-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT_3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner, by G. Rammes et al., Neuroscience Letters 306 2001, pages 81-84	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/805,222-Conf. #9133
				Filing Date	March 22, 2004
				First Named Inventor	Mark R. Burns
(Use as many sheets as necessary)				Art Unit	1625
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	22116-00011-US

	CM	Memantine is a clinically well tolerated *N*-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data, by C.G. Parsons et al., Neuropharmacology, 38, 1999, pages 735-767	
	CN	NMDA Receptor Antagonists and Antidepressant Drugs, by J. Maj, Pharmacological Research, Vol. 25, Supplement 2, 1992	
	CO	Anticonvulsant effects of eliprodil alone or combined with the glycine$_B$ receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats, by Piotr Wlaz et al., Neuropharmacology 38, 1999, pages 243-251	
	CP	Synthesis and Resolution of Racemic Eliprodil and Evaluation of the Enantiomers of Eliprodil as NMDA Receptor Antagonists, by Jorg Pabel et al., Bioorganic & Medicinal Chemistry Letters 10, 2000, pages 1377-1380	
	CQ	Affinities of 5-HT Uptake Inhibitors for 5-Ht3 Receptors in Both Binding and Functional Studies, GJ Kilpatrick et al., Brit J. Pharmacol. 1989 98 (suppl.) #17 pages 859	
	CR	The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT$_3$ and 5-HT$_4$ receptors, by A. Lucchelli et al., British Journal of Pharmacology 1995, 114, pages 1017-1025	
	CS	Higher-End Serotonin Receptors: 5-HT$_5$, 5-HT$_6$, and 5-HT$_7$, by Richard Glennon, Journal of Medicinal Chemistry, 2003, vol. 46, number 14, pages 2795-2812	
	CT	Molecular, pharmacological and functional diversity of 5-HT receptors, by Daniel Hoyer et al., Pharmacology, Biochemistry and Behavior 71, 2002, pages 533-554	
	CU	Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats, by A. Pilc et al., Neuropharmacology, 43, 2002, pages 181-187	
	CV	Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7, by John Cryan et al., European Journal of Neuroscience, Vol. 17, pages 2409-2417, 2003	
	CW	Solid Phase Synthesis of Heterocyclic Compounds from Linear Peptides: Cyclic Ureas and Thioureas, by Adel Nefzi et al., Tetrahderon Letters, vol. 38, No. 6, pages 931-934, 1997	
	CX	Antidepressants for the new millennium by Phil Skolnick, European Journal of Pharmacology 375, 1999, pages 31-40	
	CY	Mild Oxidative Cleavage of Borane-Amine Adducts from Amide Reductions: Efficient Solution- and Solid Phase Synthesis of *N*-Alkylamino Acids and Chiral Oligoamines, by Dennis Hall et al., J. Org. Chem. 1999, 64, pages 698-699,	
	CZ	Behavioural Despair in Rats: A New Model Sensitive to Antidepressant Treatments, by Roger Porsolt et al., European Journal of Pharmacology, 47 (1978), pages 379-391	
	CA1	Anxiogenic Effects of Methyl-β-Carboline-3-Carboxylate in a Light/Dark Choice Situation, by Catherine Belzung et al., Pharmacology Biochemistry & Behavior, vol. 28, pages 29-33, 1987	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	